• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

功能性和无功能促肾上腺皮质垂体腺瘤中 miRNA 表达的差异表明 miRNA 在调节皮质类固醇受体中的作用。

Difference in miRNA Expression in Functioning and Silent Corticotroph Pituitary Adenomas Indicates the Role of miRNA in the Regulation of Corticosteroid Receptors.

机构信息

Department of Molecular and Translational Oncology, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland.

Department of Cancer Pathomorphology, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland.

出版信息

Int J Mol Sci. 2022 Mar 5;23(5):2867. doi: 10.3390/ijms23052867.

DOI:10.3390/ijms23052867
PMID:35270010
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8911444/
Abstract

Corticotroph pituitary adenomas commonly cause Cushing's disease (CD), but some of them are clinically silent. The reason why they do not cause endocrinological symptoms remains unclear. We used data from small RNA sequencing in adenomas causing CD ( = 28) and silent ones ( = 20) to explore the role of miRNA in hormone secretion and clinical status of the tumors. By comparing miRNA profiles, we identified 19 miRNAs differentially expressed in clinically functioning and silent corticotroph adenomas. The analysis of their putative target genes indicates a role of miRNAs in regulation of the corticosteroid receptors expression. Adenomas causing CD have higher expression of hsa-miR-124-3p and hsa-miR-135-5p and lower expression of their target genes and . The role of hsa-miR-124-3p in the regulation of was further validated in vitro using AtT-20/D16v-F2 cells. The cells transfected with miR-124-3p mimics showed lower levels of glucocorticoid receptor expression than control cells while the interaction between miR-124-3p and 3' UTR was confirmed using luciferase reporter assay. The results indicate a relatively small difference in miRNA expression between clinically functioning and silent corticotroph pituitary adenomas. High expression of hsa-miR-124-3p in adenomas causing CD plays a role in the regulation of glucocorticoid receptor level and probably in reducing the effect of negative feedback mediated by corticosteroids.

摘要

促肾上腺皮质激素垂体腺瘤常导致库欣病(CD),但其中一些是临床无症状的。它们不引起内分泌症状的原因尚不清楚。我们使用导致 CD 的腺瘤(=28)和无症状腺瘤(=20)中的小 RNA 测序数据来探讨 miRNA 在激素分泌和肿瘤临床状态中的作用。通过比较 miRNA 图谱,我们鉴定了在临床上有功能和无功能的促肾上腺皮质激素腺瘤中差异表达的 19 个 miRNA。对其假定靶基因的分析表明 miRNA 在调节皮质类固醇受体表达中的作用。导致 CD 的腺瘤具有更高表达的 hsa-miR-124-3p 和 hsa-miR-135-5p,以及其靶基因 和 的更低表达。hsa-miR-124-3p 在调节 中的作用在体外使用 AtT-20/D16v-F2 细胞进一步得到验证。转染 miR-124-3p 模拟物的细胞显示出比对照细胞更低水平的糖皮质激素受体表达,而 miR-124-3p 和 3'UTR 之间的相互作用则通过荧光素酶报告基因测定得到证实。结果表明,临床上有功能和无功能的促肾上腺皮质激素垂体腺瘤之间的 miRNA 表达差异相对较小。导致 CD 的腺瘤中 hsa-miR-124-3p 的高表达在调节糖皮质激素受体水平中发挥作用,可能在降低皮质类固醇介导的负反馈作用方面发挥作用。

相似文献

1
Difference in miRNA Expression in Functioning and Silent Corticotroph Pituitary Adenomas Indicates the Role of miRNA in the Regulation of Corticosteroid Receptors.功能性和无功能促肾上腺皮质垂体腺瘤中 miRNA 表达的差异表明 miRNA 在调节皮质类固醇受体中的作用。
Int J Mol Sci. 2022 Mar 5;23(5):2867. doi: 10.3390/ijms23052867.
2
The expression of glucocorticoid and mineralocorticoid receptors in pituitary tumors causing Cushing's disease and silent corticotroph tumors.促肾上腺皮质激素细胞肿瘤和无功能促肾上腺皮质激素细胞瘤中糖皮质激素和盐皮质激素受体的表达。
Front Endocrinol (Lausanne). 2023 Mar 29;14:1124646. doi: 10.3389/fendo.2023.1124646. eCollection 2023.
3
Lineage-dependent role of miR-410-3p as oncomiR in gonadotroph and corticotroph pituitary adenomas or tumor suppressor miR in somatotroph adenomas via MAPK, PTEN/AKT, and STAT3 signaling pathways.通过 MAPK、PTEN/AKT 和 STAT3 信号通路,miR-410-3p 在促性腺激素和促皮质激素垂体腺瘤中作为癌基因,或在生长激素腺瘤中作为肿瘤抑制 miR,具有谱系依赖性作用。
Endocrine. 2019 Sep;65(3):646-655. doi: 10.1007/s12020-019-01960-7. Epub 2019 Jun 4.
4
Case Report: Micro-RNAs in Plasma From Bilateral Inferior Petrosal Sinus Sampling and Peripheral Blood From Corticotroph Pituitary Neuroendocrine Tumors.病例报告:双侧岩下窦采血和促肾上腺皮质激素垂体神经内分泌肿瘤外周血中的 micro-RNAs。
Front Endocrinol (Lausanne). 2022 Apr 22;13:748152. doi: 10.3389/fendo.2022.748152. eCollection 2022.
5
Expression of genes related to corticotropin production and glucocorticoid feedback in corticotroph adenomas of dogs with Cushing's disease.患有库欣病的犬促肾上腺皮质激素腺瘤中促肾上腺皮质激素产生和糖皮质激素反馈相关基因的表达
Domest Anim Endocrinol. 2009 Jan;36(1):3-12. doi: 10.1016/j.domaniend.2008.08.002. Epub 2008 Sep 18.
6
Inhibitory effects of SOM230 on adrenocorticotropic hormone production and corticotroph tumor cell proliferation in vitro and in vivo.SOM230对促肾上腺皮质激素生成及促肾上腺皮质激素分泌肿瘤细胞体外和体内增殖的抑制作用
Mol Cell Endocrinol. 2014 Aug 25;394(1-2):37-46. doi: 10.1016/j.mce.2014.07.001. Epub 2014 Jul 8.
7
Differential expression of somatostatin and dopamine receptor subtype genes in adrenocorticotropin (ACTH)-secreting pituitary tumors and silent corticotroph adenomas.生长抑素和多巴胺受体亚型基因在促肾上腺皮质激素(ACTH)分泌性垂体瘤和静止性促肾上腺皮质激素细胞腺瘤中的差异表达。
Endocr J. 2009;56(4):579-84. doi: 10.1507/endocrj.k08e-186. Epub 2009 Mar 24.
8
miR-26a plays an important role in cell cycle regulation in ACTH-secreting pituitary adenomas by modulating protein kinase Cδ.miR-26a 通过调节蛋白激酶 Cδ 在 ACTH 分泌性垂体腺瘤的细胞周期调控中发挥重要作用。
Endocrinology. 2013 May;154(5):1690-700. doi: 10.1210/en.2012-2070. Epub 2013 Mar 22.
9
Why don't corticotroph tumors always produce Cushing's disease?为什么促肾上腺皮质细胞瘤并非总会导致库欣病?
Eur J Endocrinol. 2019 Sep;181(3):351-361. doi: 10.1530/EJE-19-0338.
10
Silibinin, an HSP90 Inhibitor, on Human ACTH-Secreting Adenomas.水飞蓟宾,一种 HSP90 抑制剂,对人 ACTH 分泌性腺瘤的作用。
Neuroendocrinology. 2023;113(6):606-614. doi: 10.1159/000529710. Epub 2023 Feb 15.

引用本文的文献

1
Approaches based on natural products and miRNAs in pituitary adenomas: unveiling therapeutic intervention.垂体腺瘤中基于天然产物和微小RNA的方法:揭示治疗干预措施
Naunyn Schmiedebergs Arch Pharmacol. 2025 Jan;398(1):69-88. doi: 10.1007/s00210-024-03347-6. Epub 2024 Aug 5.
2
The expression of glucocorticoid and mineralocorticoid receptors in pituitary tumors causing Cushing's disease and silent corticotroph tumors.促肾上腺皮质激素细胞肿瘤和无功能促肾上腺皮质激素细胞瘤中糖皮质激素和盐皮质激素受体的表达。
Front Endocrinol (Lausanne). 2023 Mar 29;14:1124646. doi: 10.3389/fendo.2023.1124646. eCollection 2023.
3
Recent advances in understanding and managing pituitary adenomas.

本文引用的文献

1
High-risk pituitary adenomas and strategies for predicting response to treatment.高危垂体腺瘤及治疗反应预测策略。
Hormones (Athens). 2022 Mar;21(1):1-14. doi: 10.1007/s42000-021-00333-y. Epub 2022 Jan 21.
2
An Update on Silent Corticotroph Adenomas: Diagnosis, Mechanisms, Clinical Features, and Management.沉默性促肾上腺皮质激素腺瘤的最新进展:诊断、机制、临床特征及管理
Cancers (Basel). 2021 Dec 6;13(23):6134. doi: 10.3390/cancers13236134.
3
Effect of 3 NR3C1 Mutations in the Pathogenesis of Pituitary ACTH Adenoma.3NR3C1 突变在垂体促肾上腺皮质激素腺瘤发病机制中的作用。
垂体腺瘤的认识与管理的最新进展
Fac Rev. 2023 Mar 21;12:6. doi: 10.12703/r/12-6. eCollection 2023.
4
Emerging Roles of miRNA, lncRNA, circRNA, and Their Cross-Talk in Pituitary Adenoma.微小 RNA、长链非编码 RNA、环状 RNA 的新兴作用及其在垂体腺瘤中的相互作用。
Cells. 2022 Sep 19;11(18):2920. doi: 10.3390/cells11182920.
5
The Role of Glucocorticoid Receptor in the Pathophysiology of Pituitary Corticotroph Adenomas.糖皮质激素受体在垂体促肾上腺皮质细胞瘤发病机制中的作用。
Int J Mol Sci. 2022 Jun 9;23(12):6469. doi: 10.3390/ijms23126469.
Endocrinology. 2021 Nov 1;162(11). doi: 10.1210/endocr/bqab167.
4
Silent corticotroph pituitary adenomas: clinical characteristics, long-term outcomes, and management of disease recurrence.沉默型促肾上腺皮质激素垂体腺瘤:临床特征、长期预后及疾病复发的管理
J Neurosurg. 2021 May 7;135(6):1706-1713. doi: 10.3171/2020.10.JNS203236. Print 2021 Dec 1.
5
Food intake in early life and epigenetic modifications of pro-opiomelanocortin expression in arcuate nucleus.生命早期的食物摄入与弓状核中 pro-opiomelanocortin 表达的表观遗传修饰
Mol Biol Rep. 2021 Apr;48(4):3773-3784. doi: 10.1007/s11033-021-06340-x. Epub 2021 Apr 20.
6
Differential microRNA Expression in -Mutated and Wild-Type Corticotroph Pituitary Tumors Reflect the Difference in Protein Ubiquitination Processes.-突变型和野生型促肾上腺皮质激素垂体瘤中微小RNA的差异表达反映了蛋白质泛素化过程的差异。
J Clin Med. 2021 Jan 20;10(3):375. doi: 10.3390/jcm10030375.
7
Medical Treatment of Cushing's Disease: An Overview of the Current and Recent Clinical Trials.库欣病的治疗:当前和近期临床试验概述。
Front Endocrinol (Lausanne). 2020 Dec 8;11:648. doi: 10.3389/fendo.2020.00648. eCollection 2020.
8
PANTHER version 16: a revised family classification, tree-based classification tool, enhancer regions and extensive API.PANTHER 版本 16:修订后的家族分类、基于树的分类工具、增强子区域和广泛的 API。
Nucleic Acids Res. 2021 Jan 8;49(D1):D394-D403. doi: 10.1093/nar/gkaa1106.
9
Elevated microRNA-135b-5p relieves neuronal injury and inflammation in post-stroke cognitive impairment by targeting NR3C2.高表达 microRNA-135b-5p 通过靶向 NR3C2 减轻卒中后认知障碍中的神经元损伤和炎症。
Int J Neurosci. 2022 Jan;132(1):58-66. doi: 10.1080/00207454.2020.1802265. Epub 2020 Aug 4.
10
Differential Expression of MicroRNAs in Silent and Functioning Corticotroph Tumors.微小RNA在静止性和功能性促肾上腺皮质激素细胞肿瘤中的差异表达
J Clin Med. 2020 Jun 12;9(6):1838. doi: 10.3390/jcm9061838.